These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2404906)
21. Detection, prediction, and prognosis: blood circulating microRNA as novel molecular markers of head and neck cancer patients. Powrózek T; Porgador A; Małecka-Massalska T Expert Rev Mol Diagn; 2020 Jan; 20(1):31-39. PubMed ID: 31778325 [No Abstract] [Full Text] [Related]
22. Diagnostic accuracy of serum biomarkers for head and neck cancer: A systematic review and meta-analysis. Guerra EN; Rêgo DF; Elias ST; Coletta RD; Mezzomo LA; Gozal D; De Luca Canto G Crit Rev Oncol Hematol; 2016 May; 101():93-118. PubMed ID: 26971993 [TBL] [Abstract][Full Text] [Related]
23. Significance of serum phosphohexose isomerase in gastrointestinal cancer at different stages. Baumann M; Brand K; Giedl J; Hermanek P; Ruf S; Scheele J; Hoferichter S; Gall FP Oncology; 1988; 45(3):153-8. PubMed ID: 3368192 [TBL] [Abstract][Full Text] [Related]
24. Serum (circulating) tumor markers for breast cancer. Hayes DF Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054 [TBL] [Abstract][Full Text] [Related]
25. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558 [TBL] [Abstract][Full Text] [Related]
26. Use of serum markers in the diagnosis and management of laryngeal cancer. Mevio E; Benazzo M; Galioto P; Spriano P; Pizzala R Clin Otolaryngol Allied Sci; 1991 Feb; 16(1):90-2. PubMed ID: 2032368 [TBL] [Abstract][Full Text] [Related]
27. Clinical applications of serum tumor markers. Bates SE Ann Intern Med; 1991 Oct; 115(8):623-38. PubMed ID: 1716430 [TBL] [Abstract][Full Text] [Related]
28. Serum tumor markers for patient monitoring: a case-oriented approach illustrated with carcinoembryonic antigen. Fritsche HA Clin Chem; 1993 Nov; 39(11 Pt 2):2431-4. PubMed ID: 8222254 [TBL] [Abstract][Full Text] [Related]
29. [Differences in assay sensitivity of selected tumor markers in head and neck neoplasms]. Adamiak G; Jurkiewicz D; Polberg K; Konieczna M Otolaryngol Pol; 1995; 49 Suppl 20():99-101. PubMed ID: 9454232 [TBL] [Abstract][Full Text] [Related]
30. CA 72-4 serum marker--a new tool in the management of carcinoma patients. Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Casaldi V; Wappner G; Abbolito MR; Greiner JW Cancer Invest; 1995; 13(2):227-38. PubMed ID: 7874576 [TBL] [Abstract][Full Text] [Related]
31. [Prognostic value of tumor markers in the follow up of malignant neoplasms of the head and neck]. Grandis S; Screm MC; Cartei G Acta Otorhinolaryngol Ital; 1989; 9(6):599-604. PubMed ID: 2699147 [TBL] [Abstract][Full Text] [Related]
32. [Tumor markers in liver metastases of colorectal carcinoma]. Moreno Sierra J; Vincent E; Gea M; Ortega MD; Borque M; Madrigal J; Pimentel C; Represa J Rev Esp Enferm Dig; 1990 Sep; 78(3):139-44. PubMed ID: 1980590 [TBL] [Abstract][Full Text] [Related]
33. Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature. van Ginkel JH; Slieker FJB; de Bree R; van Es RJJ; Van Cann EM; Willems SM Oral Oncol; 2017 Dec; 75():8-15. PubMed ID: 29224828 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Molina R; Torres MD; Moragas M; Perez-Villa J; Filella X; Jo J; Farrus B; Giménez N; Traserra J; Ballesta AM Tumour Biol; 1996; 17(2):81-9. PubMed ID: 8658017 [TBL] [Abstract][Full Text] [Related]
35. Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence. Ohashi T; Komatsu S; Ichikawa D; Kosuga T; Okamoto K; Arita T; Konishi H; Morimura R; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Fujiwara H; Otsuji E Int J Clin Oncol; 2017 Oct; 22(5):897-904. PubMed ID: 28488013 [TBL] [Abstract][Full Text] [Related]
36. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions]. Yang JG; Li CL; Gong M; Zou LF Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375 [TBL] [Abstract][Full Text] [Related]
37. Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kuo WR; Lee KW; Ho KY; Tsai SM; Chiang FY; Juan KH Kaohsiung J Med Sci; 1999 Mar; 15(3):152-8. PubMed ID: 10224839 [TBL] [Abstract][Full Text] [Related]
38. [Clinical evaluation of serum immunosuppressive acidic protein (IAP) and acid soluble glycoproteins (ASP) in patients with malignant tumors]. Shibasaki K; Soga K; Toshima M; Aikawa K; Tsuruya T; Itoh T; Takahashi Y; Tsuchimochi M; Mataga I; Tsuchikawa K Shigaku; 1989 Aug; 77(2):701-11. PubMed ID: 2489324 [TBL] [Abstract][Full Text] [Related]
39. Effective head and neck tumor markers. The continuing quest. Ropka ME; Goodwin WJ; Levine PA; Sasaki CT; Kirchner JC; Cantrell RW Arch Otolaryngol Head Neck Surg; 1991 Sep; 117(9):1011-4. PubMed ID: 1910716 [TBL] [Abstract][Full Text] [Related]
40. Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers. Amiri FS Ren Fail; 2016; 38(4):530-44. PubMed ID: 26907957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]